Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Affordability topic
No spam. Unsubscribe anytime.
Agency official says drug affordability is central to access at generics conference
Summary
An agency official opened a two-day conference on generic drugs, framing affordability as an access issue and urging policies to make generics and biosimilars more available to Americans.
An agency official opened a two-day conference on generic drugs by thanking Dr. Stoddard and saying the topic affects "so many Americans." The official said affordability is an access issue, arguing that if a curative drug is priced out of reach, its population-level effectiveness is substantially reduced.
"If you have a drug that is curative...that drug was so expensive that 0.5 the population could not afford it...then on a population level that drug is only 50% effective," the agency official said. The speaker framed lowering prices as a central priority for the administration and said staff are pursuing short- and long-term options to improve access.
The official tied affordability to concrete regulatory changes discussed at the conference, including steps on biosimilars and expanded generic approvals. Attendees were urged to consider both policy and market mechanisms that can increase competition and lower out-of-pocket costs for patients.
